Blog
RSS FeedPosted by Michael Wonder on 13 Jun 2023
Planned revision of EU pharmaceutical legislation: early market access and robust evidence need not remain a contradiction in terms
13 June 2023 - On 26 April, the EU Commission presented a proposal for the revision of pharmaceutical legislation in ...
Posted by Michael Wonder on 13 May 2023
Orphan drugs: early generation of evidence urgently needed
10 May 2023 - A team led by IQWiG authors, together with Rita Banzi from the Italian Mario Negri Institute, analysed ...
Posted by Michael Wonder on 02 May 2023
Trastuzumab deruxtecan: benefits also in HER2 low breast cancer
2 May 2023 - For patients with advanced HER2 low breast cancer, IQWiG sees an additional benefit that is partly considerable ...
Posted by Michael Wonder on 17 Apr 2023
Olaparib in metastatic prostate cancer: added benefit for certain patients
17 April 2023 - Younger treatment naïve patients benefit. No relevant data were presented for previously treated patients. ...
Posted by Michael Wonder on 05 Apr 2023
Are German drug pricing regulations chasing some drug makers away, causing them to withdraw products from the market?
5 April 2023 - Germany’s pharmaceutical market is the most important one on the European continent. ...
Posted by Michael Wonder on 15 Mar 2023
Zanubrutinib in chronic lymphocytic leukaemia: additional benefit for certain patients
15 March 2023 - For adults with relapsed/refractory chronic lymphocytic leukaemia who have not yet received a BTK or BCL2 inhibitor, ...
Posted by Michael Wonder on 02 Mar 2023
Efficient RCTs with real world data for benefit assessments: accelerating evidence-based care
2 March 2023 - Together with colleagues from the Belgian HTA agency KCE, three employees of IQWiG in the BMJ are ...
Posted by Michael Wonder on 16 Feb 2023
Thomas Kaiser becomes the new head of IQWiG
16 February 2023 - The current head of the IQWiG department for drug assessment succeeds Jürgen Windeler, who is retiring after ...
Posted by Michael Wonder on 15 Feb 2023
Germany proposes to fix shortages in certain medicines
15 February 2023 - Germany's health ministry on Tuesday vowed to fix shortages in medicines for children, antibiotics and cancer ...
Posted by Michael Wonder on 02 Feb 2023
Advanced breast cancer: now a significant added benefit for trastuzumab deruxtecan
2 February 2023 - New results from an early-initiated study show advantages in overall survival. ...
Posted by Michael Wonder on 26 Jan 2023
Draft methods (version 7.0): IQWiG is extending the comment period
26 January 2023 - The new deadline is 28 February 2023. ...
Posted by Michael Wonder on 03 Jan 2023
Pertuzumab and pertuzumab with trastuzumab in breast cancer: now a minor additional clinical benefit
2 January 2023 - Advantages in overall survival and in relapses often only become apparent after a long period of ...
Posted by Michael Wonder on 08 Dec 2022
IQWiG updates its General Methods
6 December 2022 - Revision of the cost-benefit assessment and addition of the concept of application-accompanying data collection: Comments on ...
Posted by Michael Wonder on 08 Dec 2022
Osteoporosis after menopause: fewer vertebral fractures with teriparatide than with risedronate
5 December 2022 - The final report of the IQWiG on the comparative benefit assessment of bisphosphonates, teriparatide and denosumab ...
Posted by Michael Wonder on 07 Dec 2022
Differences in evidentiary requirements between European Medicines Agency and European health technology assessment of oncology drugs—can alignment be enhanced?
5 December 2022 - National health technology assessments across Europe show differences in evidentiary requirements from assessments by the EMA, affecting ...